{"altmetric_id":2300169,"counts":{"readers":{"mendeley":5,"citeulike":0,"connotea":0},"news":{"unique_users_count":5,"unique_users":["medpage_today","medicalxpress","the_asco_post","health_canal","myscience"],"posts_count":6},"total":{"posts_count":25},"twitter":{"unique_users_count":16,"unique_users":["TheLancetOncol","AleFer_endo","mtnhealthcare","rubenroa","medicineupdate","TripCancer","oncoslearning","darmtag","rincondesisifo","FactamFarmacia","CRWLibrary","aftimosp","Magil2006","BuckMatthews1","BiblioEndo","BiblioOnco"],"posts_count":18},"weibo":{"unique_users_count":1,"unique_users":["\u539a\u666e\u533b\u836f"],"posts_count":1}},"selected_quotes":["Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer","Sorafenib a new tx option for patients with iodine-refractory advanced differentiated thyroid cancer -","(Lancet) Sorafenib en ca de tiroides avanzado, metast\u00e1sico y resistente a I-131 ECA","Exciting news from a #thyroid #cancer clinical trial with Sorafenib"],"citation":{"altmetric_jid":"4f6fa6393cf058f610008b2a","authors":["Marcia S Brose","Christopher M Nutting","Barbara Jarzab","Rossella Elisei","Salvatore Siena","Lars Bastholt","Christelle de la Fouchardiere","Furio Pacini","Ralf Paschke","Young Kee Shong","Steven I Sherman","Johannes W A Smit","John Chung","Christian Kappeler","Carol Pe\u00f1a","Istv\u00e1n Moln\u00e1r","Martin J Schlumberger","Brose MS","Nutting CM","Jarzab B","Elisei R","Siena S","Bastholt L","de la Fouchardiere C","Pacini F","Paschke R","Shong YK","Sherman SI","Smit JW","Chung J","Kappeler C","Pe\u00f1a C","Moln\u00e1r I","Schlumberger MJ"],"doi":"10.1016\/s0140-6736(14)60421-9","endpage":"328","first_seen_on":"2014-04-23T23:49:42+00:00","funders":["nci"],"issns":["0140-6736","01406736","1474-547X"],"issue":"9940","journal":"The Lancet","last_mentioned_on":1414978492,"links":["http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(14)60421-9\/abstract","http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(14)60421-9\/abstract?rss=yes","http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673614604219","http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(14)60421-9\/fulltext","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24768112?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24768112","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24768112?dopt=Abstract","http:\/\/dx.doi.org\/10.1016\/S0140-6736(14)60421-9","http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736%2814%2960421-9\/abstract","http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736%2814%2960421-9\/fulltext#article_upsell"],"pdf_url":"http:\/\/download.thelancet.com\/pdfs\/journals\/lancet\/PIIS0140673614604219.pdf","pmid":"24768112","pubdate":"2014-04-24T00:00:00+00:00","publisher":"Elsevier","publisher_subjects":[{"name":"Medical And Health Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"319","subjects":["medicine"],"title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","type":"article","uri":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673614604219","volume":"384","mendeley_url":"http:\/\/www.mendeley.com\/research\/sorafenib-radioactive-iodinerefractory-locally-advanced-metastatic-diff-erentiated-thyroid-cancer-ra-1"},"altmetric_score":{"score":45.75,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":45.75},"context_for_score":{"all":{"total_number_of_other_articles":7419766,"mean":6.4517840672812,"rank":162775,"this_scored_higher_than_pct":97,"this_scored_higher_than":7256961,"rank_type":"exact","sample_size":7419766,"percentile":97},"similar_age_3m":{"total_number_of_other_articles":173534,"mean":7.1581684060095,"rank":5129,"this_scored_higher_than_pct":97,"this_scored_higher_than":168401,"rank_type":"exact","sample_size":173534,"percentile":97},"this_journal":{"total_number_of_other_articles":21974,"mean":25.540606198516,"rank":2315,"this_scored_higher_than_pct":89,"this_scored_higher_than":19656,"rank_type":"exact","sample_size":21974,"percentile":89},"similar_age_this_journal_3m":{"total_number_of_other_articles":281,"mean":55.957592857143,"rank":65,"this_scored_higher_than_pct":76,"this_scored_higher_than":216,"rank_type":"exact","sample_size":281,"percentile":76}}},"demographics":{"poster_types":{"member_of_the_public":10,"practitioner":5,"science_communicator":1},"users":{"twitter":{"cohorts":{"Science communicators (journalists, bloggers, editors)":1,"Members of the public":10,"Practitioners (doctors, other healthcare professionals)":5}},"mendeley":{"by_status":{"Student  > Doctoral Student":1,"Researcher":1,"Student  > Ph. D. Student":3},"by_discipline":{"Medicine and Dentistry":3,"Biochemistry, Genetics and Molecular Biology":1,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"twitter":{"GB":2,"AR":2,"US":1,"DE":1,"ES":2,"BE":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/TheLancetOncol\/status\/459416931104489472","license":"datasift","citation_ids":[2300169],"posted_on":"2014-04-24T19:41:46+00:00","author":{"name":"The Lancet Oncology","url":"http:\/\/www.thelancet.com","image":"https:\/\/pbs.twimg.com\/profile_images\/441608748306423808\/qlozKasq_normal.jpeg","description":"The Lancet Oncology is the world-leading clinical oncology journal publishing high-quality, peer-reviewed research and reviews, comment, news, and Commissions.","id_on_source":"TheLancetOncol","tweeter_id":"50265238","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":12049},"tweet_id":"459416931104489472"},{"url":"http:\/\/twitter.com\/AleFer_endo\/status\/459491189042196480","license":"datasift","rt":["TheLancetOncol"],"citation_ids":[2300169],"posted_on":"2014-04-25T00:36:51+00:00","author":{"name":"Alejandra Fern\u00e1ndez","image":"https:\/\/pbs.twimg.com\/profile_images\/3264443996\/0ac3f3b66e881029ac08bb233787c0ba_normal.jpeg","description":"Endocrin\u00f3loga fascinada (y un tanto desconcertada) por la vida y la web. No me sigas. Acompa\u00f1\u00e1me.","id_on_source":"AleFer_endo","tweeter_id":"1188253200","geo":{"lt":-34,"ln":-64,"country":"AR"},"followers":718},"tweet_id":"459491189042196480"},{"url":"http:\/\/twitter.com\/mtnhealthcare\/status\/461368156322557952","license":"datasift","citation_ids":[2300169],"posted_on":"2014-04-30T04:55:14+00:00","author":{"name":"MHC","url":"http:\/\/www.facebook.com\/mtnhealthcare","image":"https:\/\/pbs.twimg.com\/profile_images\/2845126333\/e08f3eaf96abc83f62b07309714ea824_normal.jpeg","description":"Providing medical care in the Sierra Nevada","id_on_source":"mtnhealthcare","tweeter_id":"921874609","geo":{"lt":null,"ln":null},"followers":1039},"tweet_id":"461368156322557952"},{"url":"https:\/\/twitter.com\/rubenroa\/status\/492823007417864192","license":"datasift","citation_ids":[2300169],"posted_on":"2014-07-26T00:05:35+00:00","author":{"name":"Ruben Roa","url":"http:\/\/medicina-general-familiar.blogspot.com","image":"https:\/\/pbs.twimg.com\/profile_images\/428849770891710464\/kgRmDYTd_normal.png","description":"Family Doctor & Epidemiologist & Health Technology Assesment","id_on_source":"rubenroa","tweeter_id":"35991485","geo":{"lt":-34.61315,"ln":-58.37723,"country":"AR"},"followers":1862},"tweet_id":"492823007417864192"},{"url":"https:\/\/twitter.com\/medicineupdate\/status\/502120344551821313","license":"datasift","citation_ids":[2300169],"posted_on":"2014-08-20T15:49:53+00:00","author":{"name":"Tom","url":"http:\/\/j.gs\/1K3w","image":"https:\/\/pbs.twimg.com\/profile_images\/3388626222\/3c70af58befec0257424ebde88c5f261_normal.png","description":"The top 5 internal medicine journals","id_on_source":"medicineupdate","tweeter_id":"174988635","geo":{"lt":null,"ln":null},"followers":3334},"tweet_id":"502120344551821313"},{"url":"https:\/\/twitter.com\/TripCancer\/status\/510915899940175872","license":"datasift","citation_ids":[2300169],"posted_on":"2014-09-13T22:20:17+00:00","author":{"name":"Trip Cancer","url":"http:\/\/www.tripdatabase.com","image":"https:\/\/pbs.twimg.com\/profile_images\/429598181408509953\/GGLCJmws_normal.jpeg","description":"All the latest oncology evidence, added to the Trip Database. Tweets are not endorsements","id_on_source":"TripCancer","tweeter_id":"2212757204","followers":494},"tweet_id":"510915899940175872"},{"url":"http:\/\/twitter.com\/oncoslearning\/status\/459116831903457282","license":"datasift","citation_ids":[2300169],"posted_on":"2014-04-23T23:49:17+00:00","author":{"name":"Matthew Kann","image":"https:\/\/pbs.twimg.com\/profile_images\/2278806311\/vrmychq6x7sz11axngho_normal.jpeg","description":"Passionate training professional","id_on_source":"oncoslearning","tweeter_id":"247486126","geo":{"lt":39.76,"ln":-98.5,"country":"US"},"followers":139},"tweet_id":"459116831903457282"},{"url":"http:\/\/twitter.com\/darmtag\/status\/459143321751793664","license":"datasift","citation_ids":[2300169],"posted_on":"2014-04-24T01:34:33+00:00","author":{"name":"Darmtag","url":"http:\/\/darmtag.wordpress.com","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000860007151\/bUdy376d_normal.png","id_on_source":"darmtag","tweeter_id":"580627607","geo":{"lt":52.5,"ln":13.41667,"country":"DE"},"followers":44},"tweet_id":"459143321751793664"},{"url":"http:\/\/twitter.com\/rincondesisifo\/status\/459594321030021121","license":"datasift","citation_ids":[2300169],"posted_on":"2014-04-25T07:26:39+00:00","author":{"name":"Carlos F. Oropesa","url":"http:\/\/elrincondesisifo.org","image":"https:\/\/pbs.twimg.com\/profile_images\/828658267513556994\/6ekL8sJD_normal.jpg","description":"Primary Care Pharmacist \u25cb Evidence Based Medicine \u25cb Knowledge Management \u25cb Dad of 2+2 \u25cb #mirrubita \u25cb Crossfit \u25cb Calistenia \u25cb MTB \u25cb Women & Wine \u25cb RT\u2260Endorsement","id_on_source":"rincondesisifo","tweeter_id":"115939053","geo":{"lt":37.18817,"ln":-3.60667,"country":"ES"},"followers":6236},"tweet_id":"459594321030021121"},{"url":"http:\/\/twitter.com\/FactamFarmacia\/status\/459594952797081601","license":"datasift","rt":["rincondesisifo"],"citation_ids":[2300169],"posted_on":"2014-04-25T07:29:10+00:00","author":{"name":"Factam Farmacia","url":"http:\/\/www.factam.com","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000034815217\/7184c9698b0ddda76b608141822b37e6_normal.jpeg","description":"Estudios de Mercado: Necesidades, Demandas, Satisfacci\u00f3n y Perfil de Clientes. Estudios Farmacoecon\u00f3micos. Creaci\u00f3n Tienda On Line, Displays, Apps,","id_on_source":"FactamFarmacia","tweeter_id":"1541322673","geo":{"lt":40.42526,"ln":-3.69063,"country":"ES"},"followers":1746},"tweet_id":"459594952797081601"},{"url":"http:\/\/twitter.com\/CRWLibrary\/status\/460737523606900737","license":"datasift","citation_ids":[2300169],"posted_on":"2014-04-28T11:09:20+00:00","author":{"name":"Cancer Library VCC","url":"http:\/\/www.wales.nhs.uk\/velindrelibrary","image":"https:\/\/pbs.twimg.com\/profile_images\/478464349476884480\/YlBsicot_normal.jpeg","description":"The only cancer specialist library service in Wales.  Supporting NHS and academic staff, students and health professionals throughout the Principality.","id_on_source":"CRWLibrary","tweeter_id":"1288296943","geo":{"lt":51.48,"ln":-3.18,"country":"GB"},"followers":650},"tweet_id":"460737523606900737"},{"url":"http:\/\/twitter.com\/aftimosp\/status\/465005682660757504","license":"datasift","citation_ids":[2300169],"posted_on":"2014-05-10T05:49:28+00:00","author":{"name":"Philippe Aftimos, MD","url":"http:\/\/be.linkedin.com\/pub\/philippe-aftimos-md\/25\/a76\/664","image":"https:\/\/pbs.twimg.com\/profile_images\/832483544064602112\/cfYg9YGh_normal.jpg","description":"Medical Oncologist and senior research physician at @JulesBordet #Brussels. Developmental therapeutics, #BreastCancer #PrecisionMedicine. Views are my own.","id_on_source":"aftimosp","tweeter_id":"177176270","geo":{"lt":50.85045,"ln":4.34878,"country":"BE"},"followers":2429},"tweet_id":"465005682660757504"},{"url":"https:\/\/twitter.com\/Magil2006\/status\/493044152217927680","license":"datasift","rt":["safh_info"],"citation_ids":[2300169],"posted_on":"2014-07-26T14:44:20+00:00","author":{"name":"Mari\u00e1ngel Gil","image":"https:\/\/pbs.twimg.com\/profile_images\/760498520252149760\/Obcoy5Is_normal.jpg","description":"Los que me conoc\u00e9is ya sab\u00e9is, los que ya sab\u00e9is no me conoc\u00e9is. Botica del hospital y otras inquietudes.","id_on_source":"Magil2006","tweeter_id":"921568016","geo":{"lt":null,"ln":null},"followers":644},"tweet_id":"493044152217927680"},{"url":"http:\/\/twitter.com\/BuckMatthews1\/status\/459186272968658944","license":"datasift","citation_ids":[2300169],"posted_on":"2014-04-24T04:25:13+00:00","author":{"name":"Buck Matthews","image":"http:\/\/pbs.twimg.com\/profile_images\/2623440717\/R03-04bAZ_24x30-STD__normal.JPG","description":"I like everything construction related. Construction is building the way to the future. Keep Construction alive with new technology and innovation.","id_on_source":"BuckMatthews1","tweeter_id":"831378612","followers":19},"tweet_id":"459186272968658944"},{"url":"https:\/\/twitter.com\/TripCancer\/status\/505087292202315776","license":"datasift","citation_ids":[2300169],"posted_on":"2014-08-28T20:19:29+00:00","author":{"name":"Trip Cancer","url":"http:\/\/www.tripdatabase.com","image":"https:\/\/pbs.twimg.com\/profile_images\/429598181408509953\/GGLCJmws_normal.jpeg","description":"All the latest oncology evidence, added to the Trip Database. Tweets are not endorsements","id_on_source":"TripCancer","tweeter_id":"2212757204","followers":494},"tweet_id":"505087292202315776"},{"url":"https:\/\/twitter.com\/BiblioEndo\/status\/529084215892393984","license":"datasift","citation_ids":[2300169],"posted_on":"2014-11-03T01:34:41+00:00","author":{"name":"BiblioEndo","image":"http:\/\/pbs.twimg.com\/profile_images\/3099962641\/f01a7d59473782fda8e1132fb29c67d9_normal.jpeg","id_on_source":"BiblioEndo","tweeter_id":"1080409621","followers":4},"tweet_id":"529084215892393984"},{"url":"https:\/\/twitter.com\/BiblioOnco\/status\/529084260595269633","license":"datasift","citation_ids":[2300169],"posted_on":"2014-11-03T01:34:52+00:00","author":{"name":"BiblioOnco","image":"http:\/\/pbs.twimg.com\/profile_images\/3099994756\/16cf97ebaeb8372a14d74476d485f677_normal.jpeg","id_on_source":"BiblioOnco","tweeter_id":"1080416587","followers":3},"tweet_id":"529084260595269633"},{"url":"http:\/\/twitter.com\/medicineupdate\/status\/461119859535794176","license":"datasift","citation_ids":[2300169],"posted_on":"2014-04-29T12:28:36+00:00","author":{"name":"Tom","url":"http:\/\/j.gs\/1K3w","image":"https:\/\/pbs.twimg.com\/profile_images\/3388626222\/3c70af58befec0257424ebde88c5f261_normal.png","description":"The top 5 internal medicine journals","id_on_source":"medicineupdate","tweeter_id":"174988635","geo":{"lt":null,"ln":null},"followers":3334},"tweet_id":"461119859535794176"}],"news":[{"title":"OncoBriefs: RT for Endometrial Ca, Aspirin, Thyroid (CME\/CE)","url":"http:\/\/www.medpagetoday.com\/HematologyOncology\/OtherCancers\/45428","license":"public","citation_ids":[2300169],"posted_on":"2014-04-25T18:30:00+00:00","summary":"(MedPage Today) -- Grade 1 or 2 endometrial cancer with no invasion or","author":{"name":"MedPage Today","url":"http:\/\/www.medpagetoday.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/262\/normal\/Screen_Shot_2016-02-09_at_10.51.03.png?1455015082"}},{"title":"Sorafenib shows success in advanced differentiated thyroid cancer patients","url":"http:\/\/medicalxpress.com\/news\/2014-04-sorafenib-success-advanced-differentiated-thyroid.html","license":"public","citation_ids":[2300169],"posted_on":"2014-04-25T12:30:01+00:00","summary":"(Medical Xpress)\u2014The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to a new study from researchers in the Abramson Cancer Center at the University of Pennsylvania published in","author":{"name":"MedicalXpress","url":"http:\/\/medicalxpress.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/152\/normal\/image.png?1369925783"}},{"title":"Progress in Differentiated Thyroid Cancer","url":"http:\/\/www.ascopost.com\/issues\/july-25,-2014\/progress-in-differentiated-thyroid-cancer.aspx","license":"public","citation_ids":[2300169],"posted_on":"2014-07-24T00:00:00+00:00","summary":"Treatment of differentiated thyroid cancer has been slow to advance. Three decades lapsed between the description of the first differentiated thyroid cancer patient being cured by radioactive iodine in the 1940s1 and the report of the study ...","author":{"name":"The ASCO Post","url":"http:\/\/www.ascopost.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/496\/normal\/Screen_Shot_2016-02-03_at_09.24.05.png?1454491455"}},{"title":"Penn Medicine Study: Sorafenib Shows Success in Advanced Differentiated Thyroid Cancer Patients","url":"http:\/\/www.healthcanal.com\/cancers\/50150-penn-medicine-study-sorafenib-shows-success-in-advanced-differentiated-thyroid-cancer-patients.html","license":"public","citation_ids":[2300169],"posted_on":"2014-04-25T07:33:00+00:00","summary":"Results of Randomized Phase III Clinical Trial Led to FDA Approval of Drug","author":{"name":"Health Canal","url":"http:\/\/www.healthcanal.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/221\/normal\/image.png?1370446573"}},{"title":"24.04 - Penn Medicine Study: Sorafenib Shows Success in Advanced Differentiated Thyroid Cancer Patients - PENN","url":"http:\/\/www.myscience.us\/news\/2014\/penn_medicine_study_sorafenib_shows_success_in_advanced_differentiated_thyroid_cancer_patients-2014-penn&rss=1","license":"public","citation_ids":[2300169],"posted_on":"2014-04-24T13:03:22+00:00","summary":"","author":{"name":"MyScience","url":"http:\/\/www.myscience.cc\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/151\/normal\/image.gif?1369927265"}},{"title":"Sorafenib Improves Progression-Free Survival in Progressive Radioactive Iodine\u2013Refractory Differentiated Thyroid Cancer","url":"http:\/\/www.ascopost.com\/issues\/july-25,-2014\/sorafenib-improves-progression-free-survival-in-progressive-radioactive-iodine%E2%80%93refractory-differentiated-thyroid-cancer.aspx","license":"public","citation_ids":[2300169],"posted_on":"2014-07-24T00:00:00+00:00","summary":"Patients with radioactive iodine\u2013\u00adrefractory locally advanced or metastatic differentiated thyroid cancer have a poor prognosis. In the double-blind phase III DECISION trial reported in The Lancet, Marcia S. Brose, MD, PhD, of Abramson Ca...","author":{"name":"The ASCO Post","url":"http:\/\/www.ascopost.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/496\/normal\/Screen_Shot_2016-02-03_at_09.24.05.png?1454491455"}}],"weibo":[{"url":"http:\/\/weibo.com\/5027187522\/B2IoJbfwd","license":"public","citation_ids":[2300169],"posted_on":"2014-05-04T03:52:29+00:00","summary":"\u5bbe\u5915\u6cd5\u5c3c\u4e9a\u5927\u5b66Abramson\u764c\u75c7\u4e2d\u5fc3\u7684Brose\u6559\u6388\u8fdb\u884c\u4e86\u4e00\u9879\u7814\u7a76\uff0c\u4ee5\u8bc4\u4f30\u6b64\u7c7b\u60a3\u8005\u53e3\u670d\u7d22\u62c9\u83f2\u5c3c\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u7ed3\u679c\u8868\u660e\uff1a\u7d22\u62c9\u83f2\u5c3c\u80fd\u663e\u8457\u6539\u5584\u653e\u5c04\u6027\u7898\u6cbb\u7597\u62b5\u6297\u7684\u4e2d\u665a\u671f\u5206\u5316\u578b\u7532\u72b6\u817a\u764c\u60a3\u8005\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff0c\u800c\u5b83\u7684\u4e0d\u826f\u53cd\u5e94\u662f\u5df2\u77e5\u5e76\u53ef\u63a7\u7684\u3002http:\/\/t.cn\/8s1lIne http:\/\/t.cn\/8sBU58e","author":{"name":"\u539a\u666e\u533b\u836f","image":"http:\/\/tp3.sinaimg.cn\/5027187522\/50\/22872624638\/1","id_on_source":"5027187522","followers":43}}]}}